Prelude
PreludeDx is a Laguna Hills-based molecular diagnostics company that develops AI-enabled multi-omic biosignature tests — DCISionRT and AidaBreast — to predict breast cancer recurrence risk and personalize radiation therapy decisions for women with early-stage disease.
- Company typePrivate
- Founded2009
- HeadquartersLaguna Hills, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Prelude firmographics
Firmographics- Name
- Prelude
- Legal name
- Prelude Corporation
- Website
- https://preludedx.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PreludeDx is a Laguna Hills-based molecular diagnostics company that develops AI-enabled multi-omic biosignature tests — DCISionRT and AidaBreast — to predict breast cancer recurrence risk and personalize radiation therapy decisions for women with early-stage disease.
- Ownership category
- akta.pro rank
Prelude industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)
- akta.pro secondary industries
- Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)
Keywords
Where Prelude is headquartered
LocationHeadquarters
- HQ city
- Laguna Hills
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Prelude business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Laboratory Diagnostic Testing Services: PreludeDx operates as a CLIA-certified laboratory offering molecular diagnostic tests (DCISionRT and AidaBreast) to healthcare providers and patients. Revenue is generated through test fees billed to insurance payers and patients. The company accepts all insurance plans and offers financial assistance programs.
- Test Commercialization: Commercialization of diagnostic tests for early-stage breast cancer. Projected revenue of $40M for current year following FDA breakthrough device designation for AidaBREAST test.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Insurance and self-pay options available |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Prelude product offering
Product offeringCore offering
PreludeDx operates a CLIA-certified molecular diagnostics laboratory that provides proprietary genomic and multi-omic biosignature tests for early-stage breast cancer. Its core products—DCISionRT for ductal carcinoma in situ (DCIS) and AidaBreast for early-stage invasive breast cancer—use AI-integrated biomarker analysis of patient tissue samples to generate Decision Scores that predict 10-year recurrence risk and identify which patients will benefit from radiation therapy. Tests are physician-ordered and results are returned within 3-5 days to support personalized treatment planning.
Product overview
PreludeDx (Prelude Corporation) is a molecular diagnostics company specializing in precision medicine for early-stage breast cancer. The company's portfolio consists of two core genomic tests: DCISionRT (launched 2017) for ductal carcinoma in situ (DCIS) patients, and AidaBreast (in development) for early-stage invasive breast cancer patients. Both tests use proprietary multi-omic biosignatures combined with AI algorithms to generate Decision Scores predicting recurrence risk and radiation therapy benefit. DCISionRT is a 7-gene biosignature while AidaBreast integrates spatial biology with multiplex protein expression and targeted RNA sequencing. The company also offers a web-based ordering portal and a second opinion service (Breast SOS).
Differentiator
Problem solved
Functional benefit
Brands
- DCISionRT: Genomic test for ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit and recurrence risk
- AidaBreast
- Breast SOS
Products and services
- DCISionRT A 7-gene genomic biosignature test for ductal carcinoma in situ (DCIS) that predicts 10-year recurrence risk and identifies which patients will benefit from radiation therapy following breast-conserving surgery. The test generates a Decision Score (0-10) and classifies patients as Low Risk, Elevated Risk, or Residual Risk. It is intended for breast cancer physicians (surgeons, radiation oncologists) treating DCIS patients and results are returned within 3-5 days.
- AidaBreast A multi-omic diagnostic assay for early-stage invasive breast cancer that integrates spatial biology (multiplex immunofluorescence), targeted RNA sequencing, and AI to predict 10-year locoregional recurrence risk and radiation therapy benefit for women following breast-conserving surgery. Targets HR+/HER2-negative early-stage invasive breast cancer patients (T1-T2, node-negative) and generates a Decision Score and Radio Resistance Index (RRI).
- Breast SOS (Second Opinion Service) A second opinion service offering for patients seeking additional consultation on DCIS diagnosis and treatment decisions, supporting personalized treatment planning through expert clinical review.
Quantifiable outcome
- DCISionRT testing changed radiation therapy recommendation in 38% of patients (n=770, p<0.0001) in PREDICT study of 2,007 patients
- +4 more outcomes
Companies that use Prelude
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Prelude technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
Prelude partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered strategic and core.
- QuanterixstrategicQuanterix and PreludeDx co-developed and validated AidaBREAST, a multi-omic assay that predicts locoregional recurrence risk and radiation therapy benefit. Quanterix's Simoa/spatial proteomics technology was integrated with RNA sequencing and AI for the assay. The assay was validated with 922 patients across US and Sweden.
- GenesisCarecoreGenesisCare partnership provides global access to DCISionRT for patients, particularly through radiation oncology centers in Australia and internationally. Enables PreludeDx to expand geographically through GenesisCare's network of cancer treatment facilities.
- Royal Melbourne HospitalstrategicRoyal Melbourne Hospital in Australia conducted the first independent validation of AidaBreast test involving over 400 women with early-stage invasive breast cancer. The validation confirmed the test's prognostic and predictive capabilities for radiation therapy decision-making.
- University of California San Francisco (UCSF)corePreludeDx licensed biomarkers and technology from UCSF for development of DCISionRT and other breast cancer diagnostic tests. Both DCISionRT and AidaBreast tests were developed from biomarkers licensed from UCSF.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Prelude competitors and assessment
Company assessmentDirect peers
- Exact Sciences: Acquired Genomic Health and Oncotype DX, the dominant 21-gene breast cancer recurrence test, making it the most direct competitor to DCISionRT in early-stage breast cancer risk stratification and treatment decision-making.
- Agendia: Developer of MammaPrint (70-gene signature) and BluePrint for early-stage breast cancer recurrence and molecular subtyping; directly competes with DCISionRT and AidaBreast in guiding adjuvant and radiation therapy decisions.
- NanoString Technologies: Markets Prosigna (PAM50) gene expression assay for breast cancer prognosis using the nCounter platform; offers an alternative genomic risk-stratification solution for postmenopausal early-stage breast cancer patients.
- Biotheranostics (Hologic): Develops Breast Cancer Index (BCI), a gene expression test predicting recurrence risk and benefit of extended endocrine therapy in early-stage HR+ breast cancer; positioned similarly to AidaBreast.
Broad incumbents
- Myriad Genetics: Established molecular diagnostics company offering EndoPredict for breast cancer recurrence risk as well as hereditary cancer tests (BRACAnalysis); competes across multiple precision oncology segments.
- Veracyte: Genomic diagnostics company with a growing breast cancer franchise (e.g., Prosigna acquired via NanoString partnership) and broader oncology/urology test menu; competes for payer mindshare and physician adoption.
- NeoGenomics: Specialized oncology reference laboratory offering comprehensive profiling and breast cancer assays; an alternative CLIA lab channel for hospitals ordering recurrence-risk testing.
- Guardant Health: Liquid biopsy and precision oncology company expanding into MRD and therapy selection; adjacent competitor as blood-based alternatives emerge for early-stage breast cancer risk stratification.
Emerging players
- Natera: Molecular diagnostics company expanding from cell-free DNA / MRD into oncology; a potential competitor for the multi-omic, AI-driven oncology testing market Prelude is targeting.
- Caris Life Sciences: Offers multi-omic tumor profiling (MI Profile) combining WES/WTS, proteomics, and AI; competes for the same physician customers seeking AI-driven precision oncology decision support.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Prelude social profiles
Digital presencePrelude compliance and trust
Trust signalCompliance3 records
Prelude financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prelude leadership team
Management profileNumber of profiles
Profiles6 records
Prelude funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prelude M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prelude
What does Prelude do?
PreludeDx operates a CLIA-certified molecular diagnostics laboratory that provides proprietary genomic and multi-omic biosignature tests for early-stage breast cancer. Its core products—DCISionRT for ductal carcinoma in situ (DCIS) and AidaBreast for early-stage invasive breast cancer—use AI-integrated biomarker analysis of patient tissue samples to generate Decision Scores that predict 10-year recurrence risk and identify which patients will benefit from radiation therapy. Tests are physician-ordered and results are returned within 3-5 days to support personalized treatment planning.
Is Prelude a public or private company?
Prelude is a private company. It is classified as venture growth investor backed and is currently operating.
When was Prelude founded?
Prelude was founded in 2009. It employs 1 to 10 people.
Where is Prelude based?
Prelude is headquartered in Laguna Hills, United States, in the North America region.
How does Prelude make money?
Two revenue lines are on record. Laboratory Diagnostic Testing Services are the primary driver. The others are test Commercialization.
Who are Prelude's main competitors?
Direct peers on record are Exact Sciences, Agendia, NanoString Technologies and Biotheranostics (Hologic). Broad incumbents are Myriad Genetics, Veracyte, NeoGenomics and Guardant Health. Emerging players are Natera and Caris Life Sciences.
Does Prelude have an API?
No public API is recorded for Prelude.
What industry is Prelude in?
Prelude's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization, with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 621511 and its SIC code is 8071.